Reblozyl OverviewLuspatercept (trade name Reblozyl; development code ACE-536) is a drug for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene. The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013 and fast track designation in 2015 for both indications. Contents 1 Clinical development 2 Structure and Function 3 Histor...
Read more Reblozyl Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Luspatercept
Recent Reblozyl Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Powder: 25mg/vial, 75mg/vial
NDC Database Records for Reblozyl: (2 results)Sorted by National Drug Code
- 59572-711 Reblozyl 25 mg Subcutaneous Injection, Powder, Lyophilized, for Solution by Celgene
- 59572-775 Reblozyl 75 mg Subcutaneous Injection, Powder, Lyophilized, for Solution by Celgene